重组人脑钠肽治疗慢性收缩性心力衰竭的近期疗效评价  

The short term therapeutic effect of rh-BNP on the chronic systolic heart failure

作　　者：王新[1] 王星[1] 杨胜[1] 王俊[1] 吴明[1] 陈月云[1] 王安才[1] 

机构地区：[1]皖南医学院弋矶山医院老年医学内科,芜湖241001

出　　处：《疑难病杂志》2010年第12期886-888,共3页Chinese Journal of Difficult and Complicated Cases

摘　　要：目的评价重组人脑钠肽(新活素)治疗慢性收缩性心力衰竭(CHF)的近期疗效与安全性。方法 31例患者随机分为常规治疗组和新活素组,常规治疗组17例给予强心、利尿、ACEI/ARB和(或)β-受体阻滞剂;新活素组14例在常规治疗基础上加用新活素1.5～2μg/kg于1～2 min内匀速静脉注射,然后以0.0075～0.01μg·kg^(-1)·min^(-1)静脉匀速泵入,持续24 h。随访1～7个月,观察2组用药前后生命体征、呼吸困难程度及相关心功能指标的变化。结果新活素组呼吸困难等症状缓解时间短于常规治疗组(26 h±9 hvs 36 h±15 h,P<0.05);在降低血脑钠肽浓度及改善左室射血分数(LVEF)方面,新活素组优于常规治疗组,但差异无统计学意义(P>0.05)。未发现与用药有关的不良反应。结论重组人脑钠肽治疗慢性收缩性心力衰竭疗效显著,安全性好。Objective To evaluate the short term therapeutic effect and safety of recombinant human brain natriuretic peptide（rh-BNP） in treatment of chronic systolic heart failure.Methods Thirty-one patients with chronic systolic heart failure were randomly divided into two groups：routine therapy group and rh-BNP group.The patients in routine therapy（n =17） group were administrated with cardiotonic,diuresis,ACEI/ARB,and/orβ-receptor blockers,and the patients in rh-BNP group（n = 14） were applied with rh-BNP（1.5～2.0μg/kg,iv.） based on conventional treatment.The left ventricular ejection fraction（LVEF）,concentration of serum BNP and rating of NYHA were observed and compared between two groups during 1～7 month follow up.Results Compared with the routine therapy group,the rating of NYHA in rh-BNP group was significantly and rapidly improved（26 h±9 h vs 36 h±15 h,P0.05）,while the LVEF and serum BNP had no significant change（P0.05）.No side effects was found in rh-BNP group.Conclusion It demonstrated that the rh-BNP has well therapeutic effect on chronic systolic heart, and the safety was reliable.

关 键 词：重组人脑钠肽 心力衰竭 慢性 收缩性 

分 类 号：R541.6[医药卫生—心血管疾病]